---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-017214"
form_type: "8-K"
ticker: "AURX"
cik: "0001091596"
company_name: "Nuo Therapeutics, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T04:29:28.931530+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Nuo Therapeutics enters interim sales agency agreement with Smith+Nephew for Aurix products

## Summary
- Amendment to Distribution Agreement grants Smith+Nephew interim sales agent role for Nuo Aurix brand to certain Smith+Nephew customers.
- Smith+Nephew receives commission on net sales of Nuo branded products sold to its customers under interim arrangement.
- Interim agency terminates by Dec 31, 2025 or earlier with 30 days written notice.
- Underlying five-year Distribution Agreement for Nuo to supply private-label Aurix to Smith+Nephew remains in effect.

## SEC filing metadata
- accession: 0001437749-25-017214
- form_type: 8-K
- ticker: AURX
- cik: 0001091596
- company_name: Nuo Therapeutics, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1091596/000143774925017214/0001437749-25-017214-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1091596/000143774925017214/aurx20250514_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-017214
- JSON: https://secwatch.observer/filing/0001437749-25-017214.json
- Plain text: https://secwatch.observer/filing/0001437749-25-017214.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.